Implementation of the World's largest measles-rubella mass vaccination campaign in Bangladesh: a process evaluation.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
10 Jul 2019
Historique:
received: 28 11 2018
accepted: 17 06 2019
entrez: 12 7 2019
pubmed: 12 7 2019
medline: 12 10 2019
Statut: epublish

Résumé

Gavi, the Vaccine Alliance, supported a mass vaccination Measles-Rubella Campaign (MRC) in Bangladesh during January-February 2014. We conducted a mixed-method process evaluation to understand the successes and challenges in implementation of the MRC. We reviewed documents for the MRC and the immunization programme in Bangladesh; observed meetings, vaccination sessions, and health facilities; and conducted 58 key informant interviews, 574 exit interviews with caregivers and 156 brief surveys with stakeholders involved in immunization. Our theory of Change for vaccination delivery guided our assessment of ideal implementation milestones and indicators to compare with the actual implementation processes. We identified challenges relating to country-wide political unrest, administrative and budgetary delays, shortage of transportation, problems in registration of target populations, and fears about safety of the vaccine. Despite these issues, a number of elements contributed to the successful launch of the MRC. These included: the comprehensive design of the campaign; strong partnerships between immunization authorities in the government system, Alliance partners, and civil society actors; and motivated and skilled health workers at different levels of the health system. The successful implementation of the MRC in spite of numerous contextual and operational challenges demonstrated the adaptive capacity of the national immunization programme and its partners that has positive implications for future introductions of Gavi-supported vaccines.

Sections du résumé

BACKGROUND BACKGROUND
Gavi, the Vaccine Alliance, supported a mass vaccination Measles-Rubella Campaign (MRC) in Bangladesh during January-February 2014.
METHODS METHODS
We conducted a mixed-method process evaluation to understand the successes and challenges in implementation of the MRC. We reviewed documents for the MRC and the immunization programme in Bangladesh; observed meetings, vaccination sessions, and health facilities; and conducted 58 key informant interviews, 574 exit interviews with caregivers and 156 brief surveys with stakeholders involved in immunization. Our theory of Change for vaccination delivery guided our assessment of ideal implementation milestones and indicators to compare with the actual implementation processes.
RESULTS RESULTS
We identified challenges relating to country-wide political unrest, administrative and budgetary delays, shortage of transportation, problems in registration of target populations, and fears about safety of the vaccine. Despite these issues, a number of elements contributed to the successful launch of the MRC. These included: the comprehensive design of the campaign; strong partnerships between immunization authorities in the government system, Alliance partners, and civil society actors; and motivated and skilled health workers at different levels of the health system.
CONCLUSIONS CONCLUSIONS
The successful implementation of the MRC in spite of numerous contextual and operational challenges demonstrated the adaptive capacity of the national immunization programme and its partners that has positive implications for future introductions of Gavi-supported vaccines.

Identifiants

pubmed: 31291922
doi: 10.1186/s12889-019-7176-4
pii: 10.1186/s12889-019-7176-4
pmc: PMC6617646
doi:

Substances chimiques

Measles Vaccine 0
Rubella Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

925

Subventions

Organisme : GAVI Alliance
ID : BGT/287/214

Références

J Infect Dis. 2003 May 15;187 Suppl 1:S223-9
pubmed: 12721917
J Infect Dis. 2003 May 15;187 Suppl 1:S299-306
pubmed: 12721929
Emerg Infect Dis. 2004 Nov;10(11):2017-21
pubmed: 15550217
J Infect Dis. 2011 Jul;204 Suppl 1:S198-204
pubmed: 21666162
J Infect Dis. 2011 Jul;204 Suppl 1:S252-9
pubmed: 21666170
J Infect Dis. 2011 Jul;204 Suppl 1:S499-505
pubmed: 21666206
J Infect Dis. 2011 Jul;204 Suppl 1:S78-81
pubmed: 21666217
J Infect Dis. 2011 Jul;204 Suppl 1:S82-9
pubmed: 21666218
J Infect Dis. 2011 Jul;204 Suppl 1:S90-7
pubmed: 21666219
Vaccine. 2014 Nov 12;32(48):6505-12
pubmed: 25261379
Glob Health Sci Pract. 2014 Jan 15;2(1):117-29
pubmed: 25276567
BMC Public Health. 2015 Nov 05;15:1100
pubmed: 26541976
BMC Infect Dis. 2016 Aug 12;16:411
pubmed: 27519586
Global Health. 2016 Oct 12;12(1):63
pubmed: 27729081

Auteurs

Haribondhu Sarma (H)

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) 68 Shahid Tajuddin Ahmed Sarani, Dhaka, 1212, Bangladesh. hsarma@icddrb.org.
Research School of Population Health, the Australian National University, Acton, ACT, 2601, Australia. hsarma@icddrb.org.

Ashwin Budden (A)

PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Sharmin Khan Luies (SK)

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) 68 Shahid Tajuddin Ahmed Sarani, Dhaka, 1212, Bangladesh.

Stephen S Lim (SS)

Institute for Health Metrics and Evaluation, 2301 5th Ave Suite 600, Seattle, WA, 98121, USA.

Md Shamsuzzaman (M)

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) 68 Shahid Tajuddin Ahmed Sarani, Dhaka, 1212, Bangladesh.

Tahmina Sultana (T)

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) 68 Shahid Tajuddin Ahmed Sarani, Dhaka, 1212, Bangladesh.

Julie K Rajaratnam (JK)

PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Laura Craw (L)

Gavi, the Vaccine Alliance, 2 Chemin des Mines, Geneva, 1202, Canton de Genève, Switzerland.

Cathy Banwell (C)

Research School of Population Health, the Australian National University, Acton, ACT, 2601, Australia.

Md Wazed Ali (MW)

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) 68 Shahid Tajuddin Ahmed Sarani, Dhaka, 1212, Bangladesh.

Md Jasim Uddin (MJ)

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) 68 Shahid Tajuddin Ahmed Sarani, Dhaka, 1212, Bangladesh.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH